Acebilustat for COVID-19: real-time analysis

Download Image

Post

c19early.org

Acebilustat for COVID-19

1 study with 120 patients

Serious outcome risk

Acebilustat

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Acebilustat studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)0%

Hospitalization (1)0%

RCTs (1)0%

Early (1)0%

00.511.5+

← Acebilustat
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Mar 30 2023	Levitt et al., Clinical Infectious Diseases, doi:10.1093/cid/ciad187	Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Mar 30 2023	80% lower progression (p=0.21), 67% worse recovery (p=0.07), and 6% improved viral clearance. RCT 120 outpatients showing no significant difference in time to sustained symptom resolution or viral clearance with acebilustat treatment. Subgroup analyses showed consistent patterns of longer symptom duration in treated participants.